Literature DB >> 22275225

Tumor spectrum in lynch syndrome, DNA mismatch repair system and endogenous carcinogens.

Vicente Medina-Arana1, Luciano Delgado, Alberto Bravo, Juana Martín, Antonia M Fernández-Peralta, Juan J González-Aguilera.   

Abstract

Inactivation of Mismatch Repair genes in Lynch Syndrome, caused by inherited mutations, decreases the ability to repair DNA errors throughout life. This deficit may allow the development of any tumor type. Nevertheless, the Syndrome develops a specific tumor spectrum associated with the disease. We think that such spectrum of tumors would be related to the action of certain endogenous carcinogens such as bile acids and estrogens that aggravate the inherited defect.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275225     DOI: 10.1002/jso.23054

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.

Authors:  Marcia Cruz-Correa; Yaritza Diaz-Algorri; Julyann Pérez-Mayoral; Wasilah Suleiman-Suleiman; Maria del Mar Gonzalez-Pons; Carlos Bertrán; Nicolás Casellas; Natalia Rodríguez; Sherly Pardo; Keyla Rivera; Rafael Mosquera; Segundo Rodriguez-Quilichini
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

2.  Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.

Authors:  Felipe Carneiro da Silva; José Roberto de Oliveira Ferreira; Giovana Tardin Torrezan; Márcia Cristina Pena Figueiredo; Érika Maria Monteiro Santos; Wilson Toshihiko Nakagawa; Rafael Canfield Brianese; Ligia Petrolini de Oliveira; Maria Dirlei Begnani; Samuel Aguiar-Junior; Benedito Mauro Rossi; Fábio de Oliveira Ferreira; Dirce Maria Carraro
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

Review 3.  Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies.

Authors:  Malak Abedalthagafi
Journal:  Oncotarget       Date:  2018-10-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.